9 completed, 5 terminated, 3 active not recruiting, 2 recruiting. 21 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 9, Terminated 5, Active not recruiting 3, Recruiting 2, Withdrawn 2 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow LGX818: new trials by email Literature Review of LGX818 trials Research Report on LGX818
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases Binimetinib, Encorafenib, Questionnaire Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2021-12-27 | 2026-04-16 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. Encorafenib, Cetuximab, FOLFIRI - BRAF V600E, Metastatic Colorectal Cancer | Phase 2 | Completed | Pierre Fabre Medicament | 107 | 2021-09-14 | 2026-04-30 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Binimetinib, Encorafenib, Ipilimumab - Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 112 | 2021-01-06 | 2026-09-15 |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Binimetinib, Encorafenib - Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 6 | 2020-11-16 | 2024-05-06 |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Binimetinib, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present | Phase 2 | Active not recruiting | Providence Health & Services | 24 | 2020-10-30 | 2026-04-13 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Sequential Combo Immuno and Target Therapy (SECOMBIT) Study LGX818, MEK162, Nivolumab - Metastatic Melanoma | Phase 2 | Completed | Fondazione Melanoma Onlus | 251 | 2016-11-14 | 2024-06-07 |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Encorafenib, Binimetinib - Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation | Phase 2 | Completed | University of Heidelberg Medical Center | 12 | 2016-06-01 | 2023-11-24 |
| Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC LGX818 - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2015-06-01 | 2020-11-13 | |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2015-01-01 | 2020-07-27 | |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma LGX818, MEK162, LEE011 - Melanoma | Phase 2 | Completed | Pfizer | 158 | 2014-07-23 | 2024-03-05 |
| LGX818 for Patients With BRAFV600 Mutated Tumors LGX818 - Solid Tumor, Hematologic Malignancies | Phase 2 | Terminated | Pfizer | 12 | 2014-01-14 | 2021-03-26 |
| LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma LGX818 - Melanoma | Phase 2 | Terminated | Array BioPharma | 15 | 2013-11-01 | 2017-01-09 |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation LGX818 - Melanoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 7 | 2013-07-01 | 2024-07-16 |
| Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. LEE011, LGX818 - Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1 / Phase 2 | Terminated | Array BioPharma | 28 | 2013-07-01 | 2016-09-13 |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer LGX818, Cetuximab, BYL719 - Colorectal Cancer | Phase 2 | Completed | Pfizer | 156 | 2012-11-23 | 2021-06-23 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (9) · Colorectal Neoplasms (4) · Colonic Neoplasms (2) · Rectal Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Lymphatic Metastasis (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Thyroid Neoplasms (1)
Pfizer (4) · Array BioPharma (3) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Academic and Community Cancer Research United (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · ECOG-ACRIN Cancer Research Group (1) · Fondazione Melanoma Onlus (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Pierre Fabre Medicament (1) · Providence Health & Services (1) · SWOG Cancer Research Network (1) · University of Heidelberg Medical Center (1)
United States (18) · Australia (6) · Canada (6) · Spain (6) · Germany (5) · Italy (5) · France (4) · Netherlands (4) · Switzerland (4) · Belgium (3) · Singapore (2) · United Kingdom (2) · Austria (1) · China (1) · Greece (1)
Array BioPharma (2) · Van K Morris (2) · Andrew E Hendifar (1) · Antoni Ribas (1) · Isabella C Glitza (1) · Leslie A Fecher (1) · Marc S. Raab, PD Dr. med. (1) · Matthew H Taylor (1) · Paolo Ascierto, MD (1) · Paul Chapman, MD (1) · Rona Yaegar, MD (1) · Shen Lin, MD (1)
PMID 32669376, PMID 34376578, PMID 35385748, PMID 36049147, PMID 36608320, PMID 36811382, PMID 38167503, PMID 39315864, PMID 40439484, PMID 40578933, PMID 41852303, PMID 41914670, PMID 42550831
2014 (2), U10CA180888 (2), P01CA168585 (1), P30CA015083 (1), U10CA180820 (1)